drugset / Trial / NCT01045096
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
RandomizedParallel-groupOpen-label
Summary
The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
Timeline
- Start
- 2010-03
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexlansoprazole | Other / unclassified | 15 mg | Oral |
| Subject | Dexlansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Dexlansoprazole | Other / unclassified | 60 mg | Oral |